HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, today announced an investor-led acquisition, which values the company at approximately $2.25 billion.
The company will continue to be run by CEO Mike Blue and his executive team. Blue will also assume the role of chairman of the board upon closing.
“Our relentless focus as a company has been speed, scale, and the urgency to offer patients a better option than any they have today,” said Blue. “This new group of partners backs category-defining companies that transform entire industries. Their support gives us the firepower to accelerate our momentum, expand into new clinical indications, and reach even more patients around the world who urgently need our breakthrough therapy.”
HistoSonics plans to expand beyond its initial focus on liver tumors to kidney, pancreas, and prostate indications, with a long-term vision of histotripsy being used across a range of clinical applications throughout the body, treating both benign and malignant conditions.
“What stood out with HistoSonics wasn’t just the technology, it was the speed and clarity with which the team turned a breakthrough into real clinical traction,” said Bryan Baum, Co-Founder and Managing Partner, K5 Global. “Hospitals are continuing to order systems, patient demand is surging, and the clinical results speak for themselves. We partnered with HistoSonics because this is one of those rare moments where the science, the execution, and the opportunity all align, and we are here to ensure it reaches every hospital in the world.”
HistoSonics, founded in 2009, received FDA De Novo clearance in October 2023 and uses non-invasive focused ultrasound energy to mechanically destroy and liquify targeted tissue and tumors at a sub-cellular level and without the invasiveness or toxicity of traditional procedures.
To date, over 2,000 patients have been treated by the Edison system at more than 50 U.S. medical centers, with another 50 planned system installations by year-end.
